February 2020
Research
Mirjam Christ-Crain Receives 2019 EJE Award for Research Achievements in Copeptin and Vasopressin-Dependent Disorders
Copeptin revealed to be a valuable and reliable diagnostic biomarker in the differential diagnosis of Diabetes insipidus
November 2019
Cardiology
Copeptin now in the new European Society of Cardiology Guidelines for the Diagnosis and Treatment of Pulmonary Embolism 2019
Acute pulmonary embolism is one of the leading causes for cardiovascular death worldwide. Clinicians can now rely on copeptin as a prognostic biomarker for the risk stratification of patients with acute pulmonary embolism, which was recently included in the new guideline from the European Society of Cardiology (ESC) for the diagnosis and treatment of acute pulmonary embolism.
July 2019
Cardiology
Multicentre cross-sectional observational registry to monitor the safety of early discharge after rule-out of acute myocardial infarction by copeptin and troponin: the Pro-Core registry
There is sparse information on the safety of early primary discharge from the emergency department (ED) after rule-out of myocardial infarction in suspected acute coronary syndrome (ACS).
Read the article in BMJ Open >
Find more studies about Copeptin >
July 2019
Diabetes insipidus
Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study
Differential diagnosis of diabetes insipidus is challenging. The most reliable approach is hypertonic saline-stimulated copeptin measurements.
Read the article in The Lancet >
Find more studies about Copeptin >
May 2019
Registration
The novel blood biomarker Copeptin is now available for clinical use in early rule-out of acute myocardial infarction and diagnosing water balance disorders
B·R·A·H·M·S Copeptin proAVP KRYPTOR has been registered in Canada allowing for faster, more reliable indirect measurement of vasopressin to improve diagnostic algorithms
May 2019
Research
European Endocrinology Award 2019 for research about Copeptin
Prof. Christ-Crain gave a lecture on “New diagnostic approaches in the diagnosis of Diabetes insipidus” at the opening ceremony of the ECE 2019, because she received the European Endocrinology Award 2019 for her research about Copeptin.
March 2019
AdPKD
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease
In the TEMPO 3:4 Trial, treatment with tolvaptan, a vasopressin V2 receptor antagonist, slowed the increase in total kidney volume and decline in estimated glomerular filtration rate (eGFR) in autosomal dominant polycystic kidney disease (ADPKD).
Read the article in Kidney International >
Find more studies about Copeptin >
